SEL + Placebo to match SEL 6 mg + Placebo to match SEL 18 mg
Phase 3Terminated 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Nonalcoholic Steatohepatitis
Conditions
Nonalcoholic Steatohepatitis
Trial Timeline
Feb 13, 2017 → Jun 19, 2019
NCT ID
NCT03053050About SEL + Placebo to match SEL 6 mg + Placebo to match SEL 18 mg
SEL + Placebo to match SEL 6 mg + Placebo to match SEL 18 mg is a phase 3 stage product being developed by Gilead Sciences for Nonalcoholic Steatohepatitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT03053050. Target conditions include Nonalcoholic Steatohepatitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03053050 | Phase 3 | Terminated |
| NCT03053063 | Phase 3 | Terminated |
Competing Products
20 competing products in Nonalcoholic Steatohepatitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VK2809 + Placebos | Viking Therapeutics | Phase 2 | 47 |
| TERN-501 + TERN-101 | Terns Pharmaceuticals | Phase 2 | 49 |
| TERN-101 | Terns Pharmaceuticals | Phase 2 | 49 |
| TERN-201 | Terns Pharmaceuticals | Phase 1 | 30 |
| Lanifibranor | Inventiva | Phase 2 | 47 |
| IVA337 + Placebo + Empagliflozin | Inventiva | Phase 2 | 47 |
| IVA337 + Placebo | Inventiva | Phase 3 | 72 |
| Colesevelam Hcl | Daiichi Sankyo | Phase 2 | 52 |
| Tirzepatide + Placebo | Eli Lilly | Phase 2 | 52 |
| AZD2693 | AstraZeneca | Phase 2 | 52 |
| Roflumilast + Pioglitazone + Placebo + Placebo | AstraZeneca | Phase 2 | 52 |
| MK-3655 + Placebo | Merck | Phase 2 | 52 |
| Efinopegdutide 20 mg/mL + Semaglutide 1.34 mg/mL | Merck | Phase 2 | 52 |
| Seladelpar + Placebos | Gilead Sciences | Phase 2 | 51 |
| Cilofexor | Gilead Sciences | Phase 1 | 32 |
| Firsocostat + Fenofibrate | Gilead Sciences | Phase 1 | 32 |
| GS-9674 + Placebo to match GS-9674 | Gilead Sciences | Phase 2 | 51 |
| SEL + FIR + CILO + Placebo to match FIR + Placebo to match CILO + Placebo to match SEL | Gilead Sciences | Phase 2 | 51 |
| GS-9450 + GS-9450 Placebo | Gilead Sciences | Phase 2 | 51 |
| Semaglutide + Firsocostat + Cilofexor | Gilead Sciences | Phase 2 | 51 |